Dr. Narla is Assistant Professor, Institute for Transformative Molecular Medicine, Harrington Distinguished Scholar (Early Career), Pardee-Gerstacker Professor in Cancer Research, Case Western Reserve University / Cleveland Medical Center and University Hospitals.
He is a physician scientist who specializes in the care of high-risk cancer patients. As a scientist, Dr. Narla played a central role in identifying a new gene family which regulates cancer growth and spread. He is developing a drug that would help treat patients with several cancers such as leukemia, prostate, lung and breast cancer.
His laboratory is focused on the identification and characterization of the key negative regulators, tumor suppressor proteins, of cancer development and progression. Dr. Narla’s laboratory focuses on the mechanisms that drive cancer progression and treatment resistance to conventional and targeted molecular agents.
His accolades as a principal investigator include the Howard Hughes Medical Institute Physician-Scientist Early Career Award, and the Irma T. Hirschl / Monique Weill-Caulier Trust Scholar Award. He has over 50 publications in journals including Nature Genetics, Science, Science Translational Medicine and the Journal of Clinical Investigation.
He attended Santa Clara University, received his MD and PHD from the Mount Sinai School of Medicine, completed his internship, residency and fellowships at the Mount Sinai Hospital, and joined the faulty at the Mount Sinai School of Medicine. He moved to University Hospitals / Case Western Reserve University in 2012.
Education & Training
1997, Santa Clara University
Medical / Professional School(s)
2006, Mount Sinai School of Medicine
2008, Internal Medicine - Mount Sinai Hospital
2012, Medical Genetics - Mount Sinai Hospital
Cancer Genetics, High Risk Breast Cancer Care, Internal Medicine
Case Western Reserve University - Wolstein Research Building
2103 Cornell Rd
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2015, Goutham Narla, MD, PhD disclosed the following Outside Relationships with Industry:
BioMotiv - Consulting payments
Dual Therapeutics - Ownership